Health Care

Commentary

Expand Medicaid? Democrats’ plan would increase waste, fraud and debt

If Democrats can’t get “Medicare-for-all,” it seems they’ll settle for “Medicaid-for-most.” Last month, the House of Representatives passed a bill that would supposedly “stabilize” ObamaCare by lavishing billions of dollars on Medicaid. To pay for that effort, the bill’s proponents envision cutting Medicare by nearly $450 billion over 10 years. Democrats are also lobbying states to expand the program to able-bodied, ...
Commentary

Telehealth’s Success During COVID-19 Shows Need to Empower Health Care Innovators

The COVID-19 crisis has tested America’s health care system like no other event in recent memory. One irony during this pandemic is that America has actually experienced the promise of health care innovation in an important way, namely through telehealth. Telehealth allows patients to talk with their doctors online using ...
Health Care

Sally C. Pipes Discuss Obamacare Supreme Court Hearing on the Kim Monson Show

Sally C. Pipes joined the Kim Monson Show to discusses the pending U.S. Supreme Court hearing for Obamacare. Pipes explains that we are still a year or more way from a final decision, with hearings scheduled for the fall and a final decision expected 2021. Pipes and Monson also discuss ...
Business & Economics

Wayne Winegarden – Empowering Entrepreneurs to Address America’s Health Care Challenges

PRI Senior Fellow in Business and Economics Dr. Wayne Winegarden joins us to discuss the latest study in the “Breaking Down Barriers to Opportunity” series, which makes the case that future medical innovation will be hindered unless state and federal policymakers embrace health care entrepreneurship.
Coronavirus

Dr. Henry Miller and John Batchelor Review FDA COVID-19 Guidelines

PRI’s Dr. Henry Miller joins the John Batchelor Show to review the latest developments with the vaccine guidelines and the FDA. The FDA testified before Congress that they will have complicated guidelines for a potential COVID-19 vaccine. Miller mentioned that the FDA guidelines are reassuring as it indicates that future ...
Commentary

Coronavirus drug cost – Ignore critics. Here’s why the price is right

Last week, Gilead Sciences announced that it would sell a five-day course of its coronavirus drug, remdesivir, for just over $3,100. The antiviral, currently the only medication proven to speed recovery from COVID-19, received FDA approval in May. Some Democratic lawmakers and policy experts attacked remdesivir’s price as soon as it was announced. They claim that Gilead could sell the drug ...
Commentary

Democrats Remain Jealous Of Britain’s Healthcare Catastrophe

If there was ever any doubt about the dangers of single-payer health care, the United Kingdom’s experience with COVID-19 should settle the matter. Weeks after the pandemic’s peak, the nation’s government-run health system, the National Health Service, is still subjecting patients to life-threatening treatment delays. By the NHS’s own admission, ...
Commentary

We must relax restrictions on foreign doctors

The Trump administration just made it a bit easier for foreign doctors to join the fight against the coronavirus. This month, U.S. Citizenship and Immigration Services authorized foreign doctors in the Conrad 30 program to conduct telehealth visits across state lines. Previously, these doctors — up to 30 per state ...
Commentary

Learning The Right Lessons From The Race For An Effective Covid-19 Treatment

On June 29, 2020 Gilead announced its price for remdesivir – an antiviral medication that has shown efficacy shortening the recovery time for patients with Covid-19. This price announcement provides several important lessons for the U.S. healthcare system. First, and perhaps most important, innovation is essential for winning the war against Covid-19. ...
Commentary

The coronavirus’s silent dental epidemic

By: Henry Miller, M.S., M.D., and Shiv Sharma, DDS As the nation slowly emerges from lockdown, we’re beginning to appreciate the full impact of the pandemic and that the sickness and death directly caused by the virus are only part of the picture. The three-month-plus suspension of routine, non-emergency medical ...
Commentary

Expand Medicaid? Democrats’ plan would increase waste, fraud and debt

If Democrats can’t get “Medicare-for-all,” it seems they’ll settle for “Medicaid-for-most.” Last month, the House of Representatives passed a bill that would supposedly “stabilize” ObamaCare by lavishing billions of dollars on Medicaid. To pay for that effort, the bill’s proponents envision cutting Medicare by nearly $450 billion over 10 years. Democrats are also lobbying states to expand the program to able-bodied, ...
Commentary

Telehealth’s Success During COVID-19 Shows Need to Empower Health Care Innovators

The COVID-19 crisis has tested America’s health care system like no other event in recent memory. One irony during this pandemic is that America has actually experienced the promise of health care innovation in an important way, namely through telehealth. Telehealth allows patients to talk with their doctors online using ...
Health Care

Sally C. Pipes Discuss Obamacare Supreme Court Hearing on the Kim Monson Show

Sally C. Pipes joined the Kim Monson Show to discusses the pending U.S. Supreme Court hearing for Obamacare. Pipes explains that we are still a year or more way from a final decision, with hearings scheduled for the fall and a final decision expected 2021. Pipes and Monson also discuss ...
Business & Economics

Wayne Winegarden – Empowering Entrepreneurs to Address America’s Health Care Challenges

PRI Senior Fellow in Business and Economics Dr. Wayne Winegarden joins us to discuss the latest study in the “Breaking Down Barriers to Opportunity” series, which makes the case that future medical innovation will be hindered unless state and federal policymakers embrace health care entrepreneurship.
Coronavirus

Dr. Henry Miller and John Batchelor Review FDA COVID-19 Guidelines

PRI’s Dr. Henry Miller joins the John Batchelor Show to review the latest developments with the vaccine guidelines and the FDA. The FDA testified before Congress that they will have complicated guidelines for a potential COVID-19 vaccine. Miller mentioned that the FDA guidelines are reassuring as it indicates that future ...
Commentary

Coronavirus drug cost – Ignore critics. Here’s why the price is right

Last week, Gilead Sciences announced that it would sell a five-day course of its coronavirus drug, remdesivir, for just over $3,100. The antiviral, currently the only medication proven to speed recovery from COVID-19, received FDA approval in May. Some Democratic lawmakers and policy experts attacked remdesivir’s price as soon as it was announced. They claim that Gilead could sell the drug ...
Commentary

Democrats Remain Jealous Of Britain’s Healthcare Catastrophe

If there was ever any doubt about the dangers of single-payer health care, the United Kingdom’s experience with COVID-19 should settle the matter. Weeks after the pandemic’s peak, the nation’s government-run health system, the National Health Service, is still subjecting patients to life-threatening treatment delays. By the NHS’s own admission, ...
Commentary

We must relax restrictions on foreign doctors

The Trump administration just made it a bit easier for foreign doctors to join the fight against the coronavirus. This month, U.S. Citizenship and Immigration Services authorized foreign doctors in the Conrad 30 program to conduct telehealth visits across state lines. Previously, these doctors — up to 30 per state ...
Commentary

Learning The Right Lessons From The Race For An Effective Covid-19 Treatment

On June 29, 2020 Gilead announced its price for remdesivir – an antiviral medication that has shown efficacy shortening the recovery time for patients with Covid-19. This price announcement provides several important lessons for the U.S. healthcare system. First, and perhaps most important, innovation is essential for winning the war against Covid-19. ...
Commentary

The coronavirus’s silent dental epidemic

By: Henry Miller, M.S., M.D., and Shiv Sharma, DDS As the nation slowly emerges from lockdown, we’re beginning to appreciate the full impact of the pandemic and that the sickness and death directly caused by the virus are only part of the picture. The three-month-plus suspension of routine, non-emergency medical ...